Therapeutics News

MIAMI BEACH, Fla. — Energy-based devices are emerging within dermatology, showing improvements in technology and outcomes, according to a presenter at South Beach Symposium.

MIAMI BEACH, Fla. — Anti-interleukin-23 agents tildrakizumab, guselkumab, risankizumab and mirikizumab are effective in treating patients with psoriasis, with one of the longest remission durations of any drug currently in use, according to a presenter at South Beach Symposium.

MIAMI BEACH, Fla. — Many new products and emerging therapies are being studied in clinical trials to treat acne, rosacea and molluscum contagiosum, according to a presenter at South Beach Symposium.

MIAMI BEACH, Fla. — JAK inhibitors are being studied to treat patients with psoriasis and atopic dermatitis, with many showing promising outcomes, according to a presenter at South Beach Symposium.

The novel interleukin 13 inhibitor lebrikizumab improved skin lesions, pruritis and quality of life among adults with moderate to severe atopic dermatitis, according to data from a phase 2b trial published in JAMA Dermatology.

MIAMI BEACH, Fla. — Microneedling treatments rejuvenate skin by reducing scars and signs of aging and also enhancing product absorption, according to a presenter at South Beach Symposium.

Rituximab may be a promising option for treatment-refractory childhood-onset lupus erythematosus panniculitis, according to a retrospective, observational case series published in JAMA Dermatology.

MAUI, HAWAII — Treating severe acne with isotretinoin comes with several important considerations, two experts told Maui Derm attendees.

MIAMI BEACH, Fla. — Despite the many non-invasive and minimally-invasive techniques available on the U.S. market to improve cellulite, an unmet need for a ‘holy grail’ treatment remains, according to a presenter at South Beach Symposium.

Eli Lilly and Company and Incyte announced that baricitinib met its primary endpoint in the BREEZE-AD4 and BREEZE-AD5 studies in patients with moderate to severe atopic dermatitis, according to two press releases.